KRAS and neoplasm: Combination chemotherapy using gemcitabine/(n)ab-paclitaxel (GnP) with MRTX1133, a KRAS G12D inhibitor, showed a significant reduction in relapse and longer tumor growth inhibition in both primary and metastatic settings [92].